{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T11:50:30Z","timestamp":1780055430339,"version":"3.54.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1016\/j.clgc.2016.07.026","type":"journal-article","created":{"date-parts":[[2016,8,9]],"date-time":"2016-08-09T13:09:27Z","timestamp":1470748167000},"page":"320-325","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["Prostate-Specific Antigen Flare Phenomenon Induced by Abiraterone Acetate in Chemotherapy-Naive Patients With Metastatic Castration-Resistant Prostate Cancer"],"prefix":"10.1016","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8340-0023","authenticated-orcid":false,"given":"Yujiro","family":"Ueda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuaki","family":"Matsubara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken-Ichi","family":"Tabata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takefumi","family":"Satoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoto","family":"Kamiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyoshi","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Kawahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroji","family":"Uemura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2016.07.026_bib1","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.eururo.2013.08.008","article-title":"Castration-resistant prostate cancer: from new pathophysiology to new treatment","volume":"65","author":"Sridhar","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2016.07.026_bib2","first-page":"69","article-title":"Global cancer statistics","volume":"61","author":"Jemal","year":"2011","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clgc.2016.07.026_bib3","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa1209096","article-title":"Abiraterone in metastatic prostate cancer without previous chemotherapy","volume":"368","author":"Ryan","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2016.07.026_bib4","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","article-title":"Abiraterone and increased survival in metastatic prostate cancer","volume":"364","author":"de Bono","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2016.07.026_bib5","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1056\/NEJMoa1405095","article-title":"Enzalutamide in metastatic prostate cancer before chemotherapy","volume":"371","author":"Beer","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2016.07.026_bib6","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","article-title":"Increased survival with enzalutamide in prostate cancer after chemotherapy","volume":"367","author":"Scher","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2016.07.026_bib7","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1213755","article-title":"Alpha emitter radium-223 and survival in metastatic prostate cancer","volume":"369","author":"Parker","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2016.07.026_bib8","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(10)61389-X","article-title":"Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial","volume":"376","author":"de Bono","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.clgc.2016.07.026_bib9","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1200\/JCO.2007.12.4487","article-title":"Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group","volume":"26","author":"Scher","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2016.07.026_bib10","doi-asserted-by":"crossref","first-page":"3170","DOI":"10.1158\/1078-0432.CCR-14-1549","article-title":"Correlation between prostate-specific antigen kinetics and overall survival in abiraterone acetate-treated castration-resistant prostate cancer patients","volume":"21","author":"Xu","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clgc.2016.07.026_bib11","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1186\/s12885-016-2260-y","article-title":"Dynamic changes of alkaline phosphatase are strongly associated with PSA-decline and predict best clinical benefit earlier than PSA-changes under therapy with abiraterone acetate in bone metastatic castration resistant prostate cancer","volume":"16","author":"Mikah","year":"2016","journal-title":"BMC Cancer"},{"key":"10.1016\/j.clgc.2016.07.026_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.eururo.2016.02.055","article-title":"Prostate-specific antigen decline after 4 weeks of treatment with abiraterone acetate and overall survival in patients with metastatic castration-resistant prostate cancer [e-pub ahead of print]","author":"Rescigno","year":"2016","journal-title":"Eur Urol"},{"issue":"12 suppl","key":"10.1016\/j.clgc.2016.07.026_bib13","doi-asserted-by":"crossref","first-page":"3799","DOI":"10.1002\/1097-0142(19931215)72:12+<3799::AID-CNCR2820721707>3.0.CO;2-9","article-title":"Is disease flare a problem?","volume":"72","author":"Mahler","year":"1993","journal-title":"Cancer"},{"key":"10.1016\/j.clgc.2016.07.026_bib14","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/sj.pcan.4500784","article-title":"Bicalutamide vs cyproterone acetate in preventing flare with LHRH analogue therapy for prostate cancer\u2014a pilot study","volume":"8","author":"Sugiono","year":"2005","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.clgc.2016.07.026_bib15","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/PL00012076","article-title":"Inhibition of PSA flare in prostate cancer patients by administration of flutamide for 2 weeks before initiation of treatment with slow-releasing LH-RH agonist","volume":"6","author":"Noguchi","year":"2001","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.clgc.2016.07.026_bib16","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1002\/pros.21024","article-title":"PSA surge\/flare-up in patients with castration-refractory prostate cancer during the initial phase of chemotherapy","volume":"69","author":"Nelius","year":"2009","journal-title":"Prostate"},{"key":"10.1016\/j.clgc.2016.07.026_bib17","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1016\/j.ejca.2014.03.015","article-title":"Prostate-specific antigen flare induced by cabazitaxel-based chemotherapy in patients with metastatic castration-resistant prostate cancer","volume":"50","author":"Angelergues","year":"2014","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clgc.2016.07.026_bib18","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.clgc.2014.06.010","article-title":"PSA flare with abiraterone in patients with metastatic castration-resistant prostate cancer","volume":"13","author":"Burgio","year":"2015","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.clgc.2016.07.026_bib19","doi-asserted-by":"crossref","first-page":"191","DOI":"10.12788\/jcso.0045","article-title":"PSA flare after initiation of abiraterone acetate","volume":"12","author":"Narmala","year":"2014","journal-title":"J\u00a0Community Support Oncol"},{"key":"10.1016\/j.clgc.2016.07.026_bib20","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1111\/cas.12496","article-title":"Phase-1 study of abiraterone acetate in chemotherapy-na\u00efve Japanese patients with castration-resistant prostate cancer","volume":"105","author":"Matsubara","year":"2014","journal-title":"Cancer Sci"},{"key":"10.1016\/j.clgc.2016.07.026_bib21","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1093\/jjco\/hyu149","article-title":"A\u00a0phase 2 trial of abiraterone acetate in Japanese men with metastatic castration-resistant prostate cancer and without prior chemotherapy (JPN-201 study)","volume":"44","author":"Matsubara","year":"2014","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.clgc.2016.07.026_bib22","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1186\/1472-6963-14-252","article-title":"Drug costs in the management of metastatic castration-resistant prostate cancer in Canada","volume":"14","author":"Dragomir","year":"2014","journal-title":"BMC Health Serv Res"},{"key":"10.1016\/j.clgc.2016.07.026_bib23","doi-asserted-by":"crossref","first-page":"4854","DOI":"10.1158\/1078-0432.CCR-11-0815","article-title":"Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response","volume":"17","author":"Ryan","year":"2011","journal-title":"Clin Cancer Res"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767316302294?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767316302294?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:25:47Z","timestamp":1761564347000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767316302294"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["S1558767316302294"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2016.07.026","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2017,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prostate-Specific Antigen Flare Phenomenon Induced by Abiraterone Acetate in Chemotherapy-Naive Patients With Metastatic Castration-Resistant Prostate Cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2016.07.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}